Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease

作者：Jeffery M. Vance, Lindsay A. Farrer, Yadong Huang, Carlos Cruchaga, Bradley T. Hyman, Margaret A. Pericak‐Vance, Alison Goate, Michael D. Greicius, Anthony J. Griswold, Jonathan L. Haines, Julia TCW, Gerard D. Schellenberg, Li‐Huei Tsai, Joachim Herz, David M. Holtzman · 发表于：Annals of Neurology · 年份：2024 · DOI：10.1002/ana.26864 · 被引用次数：50 · 研究领域：Alzheimer's disease research and treatments、Dementia and Cognitive Impairment Research、GDF15 and Related Biomarkers

Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625-634.